Starling Oncology Overview
Get informed when a big investor buys or sells
+ Follow-21.77
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Starling Oncology (STLN) currently reports a P/E ratio of -21.77. That is below the sector sector average of 24.62. Use the charts on this page to explore Starling Oncology's P/E ratio history and peer comparisons.
Starling Oncology's P/E ratio of -21.77 is lower than the its sector sector average of 24.62. That is roughly 188.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Starling Oncology's market price to a fundamental measure such as earnings, sales, or book value. At -21.77, STLN can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -21.77, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 24.62. From there, open related valuation or income-statement pages for Starling Oncology, and consider following STLN for alerts when major investors trade the stock.
